This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Genzyme Corporation. Active years: 2019-2023.
Company Filing History:
Years Active: 2019-2023
Title: The Innovations of Antonius Song
Introduction
Antonius Song is a notable inventor based in Dublin, California. He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) technologies. With a total of 3 patents to his name, his work has the potential to impact the treatment of various diseases.
Latest Patents
One of Antonius Song's latest patents focuses on a novel RNAi molecule. This invention includes a first strand containing a guide sequence and a second strand comprising a non-guide sequence. The non-guide sequence features a bulge opposite the seed region of the guide sequences, which is crucial for its function. This RNAi technology is particularly aimed at treating Huntington's disease. Additionally, the patent provides expression cassettes, vectors such as rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors, as well as cells, viral particles, and pharmaceutical compositions containing the RNAi. Methods and kits related to the use of this RNAi for treating Huntington's disease are also included in the patent.
Career Highlights
Antonius Song is currently employed at Genzyme Corporation, where he continues to innovate in the field of biotechnology. His work at Genzyme has allowed him to collaborate with other talented professionals in the industry.
Collaborations
Some of his notable coworkers include Sergio Pablo Sardi and Brenda Richards. Their collective expertise contributes to the advancement of their projects and the overall mission of Genzyme Corporation.
Conclusion
Antonius Song's contributions to RNAi technology represent a significant advancement in the treatment of Huntington's disease. His innovative work at Genzyme Corporation showcases the potential of biotechnology to improve health outcomes.